Last updated: 2026-09-09 08:42:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Precigen, Inc. (PGEN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $6.90, with a market capitalisation of $2.54B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.99 to $7.72. This page covers its latest market performance, valuation, price trends and company information.
$2.54B | |
$6.92 | |
$11.10 | |
$0.65 | |
$6.87 | |
241.00 | |
5.11M | |
-- | |
$7.72 | |
$2.99 | |
-- | |
-- |
Precigen, Inc. (PGEN) is trading at $6.90 in pre-market trading as of 2026-09-09 08:15:00, up 0.42% ($0.03) from the previous close of $6.87
Pre-market trading shows how investors are pricing PGEN before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Precigen, Inc. (PGEN) moved from $6.95 to $6.90, representing a decline of 0.73% ($0.05).
The stock traded between $6.60 and $7.27 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 2.78 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 82.7%
PGEN is currently trading at $6.90, placing it 82.7% of the way from its 52-week low of $2.99 to its 52-week high of $7.72. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 47 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Precigen, Inc. (PGEN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.